Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

FDA accepts IND for Arno Therapeutics' Pan-DAC/Akt inhibitor, AR-42

March 19, 2009

Quest forms alliance with IntelligentNano for nanotechnology-based SL-052

March 19, 2009

Sopherion completes enrollment in phase III Myocet breast cancer study

March 19, 2009

Novel dual MEK/ERK inhibitor shows antitumor activity

March 19, 2009

Spectrum acquires former partner RIT Oncology and rights to Zevalin for NHL

March 19, 2009

Synta initiates phase I/II clinical trial of STA-9090 in hematologic malignancies

March 18, 2009

Allos Therapeutics' pralatrexate granted European orphan drug designation for bladder cancer

March 18, 2009

Samtheo and Moffitt sign license agreement for Akt inhibitor LD-101

March 17, 2009

Clavis Pharma announces phase II elacytarabine results

March 17, 2009

YM BioSciences enrolls first patient into multinational nimotuzumab trial in NSCLC

March 16, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...